STOCK TITAN
  1. Home
  2. News
  3. CADL

Candel Therapeutics, Inc. - CADL STOCK NEWS

Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.

Candel Therapeutics, Inc. (CADL) is a Massachusetts-based biotechnology company, also known as Advantagene, Inc., specializing in the development of cutting-edge immuno-oncology platforms aimed at treating solid tumors. The company's focus is on leveraging the body's immune system to combat cancer through innovative viral immunotherapies.

At the core of Candel Therapeutics' technology are two proprietary platforms: the Gene Mediated Cytotoxic Immunotherapy (GMCI™) platform and the RQNestin34.5 platform. Designed as an 'off-the-shelf' solution, GMCI™ aims to generate a personalized and precise immune response against cancer, utilizing the patient's own immune system. The RQNestin34.5 platform, on the other hand, is centered around the use of genetically modified herpes simplex virus (HSV) constructs to target and destroy cancer cells.

As a clinical-stage biopharmaceutical company, Candel Therapeutics is dedicated to translating its scientific advancements into viable treatments for patients. The company has made substantial progress with its platforms, demonstrating promising results in clinical studies aiming to establish the efficacy and safety of these novel therapies.

Among the company's recent highlights is its presentation at the American Society of Clinical Oncology (ASCO), where it shared significant updates on its ongoing projects. Candel Therapeutics continues to engage in strategic partnerships and collaborations to advance its mission of making effective cancer treatments accessible to patients globally.

Candel Therapeutics is committed to maintaining robust investor relations, offering transparent updates and clear communication about its financial health, project milestones, and future directions. The company's leadership frequently engages with stakeholders to ensure alignment with their goals and expectations.

For the latest news and detailed financial information, investors and interested parties can contact Theodore Jenkins, Vice President of Investor Relations and Business Development, at tjenkins@candeltx.com or Kyle Evans, Account Director at ICR Westwicke, at CandelPR@westwicke.com.

News

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Rhea-AI Summary
Candel Therapeutics, Inc. (CADL) receives Orphan Drug Designation from the FDA for CAN-2409, a promising multimodal biological immunotherapy candidate for pancreatic cancer. Clinical trial data shows significant improvement in overall survival rates and safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.75%
Tags
clinical trial
-
News

Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

Rhea-AI Summary
Candel Therapeutics, Inc. presents a first-in-class immunotherapy candidate for solid tumors, inducing tertiary lymphoid structures for improved anti-tumor immunity. The candidate, developed from the enLIGHTEN™ Discovery Platform, shows promising results in inhibiting tumor growth and enhancing response to immune checkpoint inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.84%
Tags
clinical trial
-
News

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Rhea-AI Summary
Candel Therapeutics (CADL) announces positive interim data showing significant improvements in overall survival in patients with pancreatic cancer treated with CAN-2409. Survival rates at 24 and 36 months were notably higher in the CAN-2409 group compared to the control group. The treatment was well tolerated with no new safety signals observed. The FDA granted Fast Track Designation for CAN-2409 in combination with valacyclovir for pancreatic cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
280.95%
Tags
clinical trial
News

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

Rhea-AI Summary
Candel Therapeutics, Inc. announces positive data from ongoing phase 1b clinical trial of CAN-3110 for rHGG patients, showing promising results in overall survival and tolerability. The company received FDA Fast Track Designation for CAN-3110 in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.76%
Tags
clinical trial
-
News

Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

Rhea-AI Summary
Candel Therapeutics, Inc. reported financial results for Q4 2023, with positive clinical trial outcomes for CAN-2409 in pancreatic cancer and CAN-3110 in high-grade glioma. The company received FDA Fast Track Designations for both treatments, showing improved survival rates compared to standard care. Candel anticipates significant data readouts in 2024 across various cancer platforms, including a potentially registrational phase 3 trial for prostate cancer. Financially, research and development expenses increased due to activities supporting CAN-2409 programs, resulting in a net loss for Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
earnings
-
News

Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate

Rhea-AI Summary
Candel Therapeutics, Inc. (CADL) will present a poster at the AACR Annual Meeting on a first-in-class immunotherapy candidate for solid tumors, accelerating the unveiling of the second enLIGHTEN™ program. The presentation focuses on inducing tertiary lymphoid structures as a novel therapeutic strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
conferences
News

CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

Rhea-AI Summary
Candel Therapeutics, Inc. (CADL) receives FDA Fast Track Designation for CAN-3110, a promising oncolytic viral immunotherapy candidate for recurrent high-grade glioma. Positive results from the phase 1b clinical trial show a nearly doubled median overall survival with a single injection, highlighting the therapy's potential to address the unmet needs in this therapy-resistant condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.5%
Tags
clinical trial
-
News

Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts

Rhea-AI Summary
Candel Therapeutics, Inc. (Nasdaq: CADL) has highlighted upcoming milestones, including data readouts in lung, pancreatic, brain, and prostate cancer, as well as recent successes in immunotherapy. The company received Fast Track Designation from the FDA for its product candidate, CAN-2409, and reported positive clinical trial data for CAN-3110. These developments position Candel for progress and differentiation in the cancer therapeutics market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
-
News

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

Rhea-AI Summary
Candel Therapeutics, Inc. (Candel) (Nasdaq: CADL) has been granted Fast Track Designation by the FDA for its lead investigational adenovirus asset CAN-2409 plus prodrug for the treatment of pancreatic ductal adenocarcinoma (PDAC) to improve overall survival. The company presented encouraging overall survival and immunological biomarker data based on an interim analysis of the randomized, phase 2 clinical trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The estimated survival rate of patients who received the CAN-2409 plus prodrug regimen was 71.4% at both 24 and 36 months, compared to only 16.7% in patients treated with standard of care (SoC) chemoradiation prior to surgery alone. Candel remains on track to release updated overall survival data in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.23%
Tags
clinical trial
News

Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409

Rhea-AI Summary
Candel Therapeutics, Inc. (CADL) strategically restructures to focus on developing CAN-3110 and the enLIGHTEN™ Discovery Platform, reducing workforce by 50% to extend cash runway into Q4 2024. The company aims to prioritize spend on clinical data readouts for CAN-2409 in non-small cell lung cancer, pancreatic cancer, and prostate cancer in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.16%
Tags
none

FAQ

What is the current stock price of Candel Therapeutics (CADL)?

The current stock price of Candel Therapeutics (CADL) is $6.14 as of September 6, 2024.

What is the market cap of Candel Therapeutics (CADL)?

The market cap of Candel Therapeutics (CADL) is approximately 194.7M.

What does Candel Therapeutics, Inc. specialize in?

Candel Therapeutics focuses on developing immuno-oncology platforms aimed at treating solid tumors using viral immunotherapies.

What are the main platforms developed by Candel Therapeutics?

The main platforms are the Gene Mediated Cytotoxic Immunotherapy (GMCI™) platform and the RQNestin34.5 platform.

How does the GMCI™ platform work?

The GMCI™ platform generates a personalized immune response against cancer using the patient's own immune system.

What is unique about the RQNestin34.5 platform?

The RQNestin34.5 platform uses genetically modified herpes simplex virus (HSV) constructs to target and destroy cancer cells.

Is Candel Therapeutics a clinical-stage company?

Yes, Candel Therapeutics is a clinical-stage biopharmaceutical company focused on viral immunotherapies for cancer treatment.

What recent achievements has Candel Therapeutics made?

Candel Therapeutics presented significant updates at the American Society of Clinical Oncology (ASCO) and continues to progress in its clinical studies.

Who can I contact for investor relations at Candel Therapeutics?

You can contact Theodore Jenkins, Vice President of Investor Relations and Business Development, at tjenkins@candeltx.com.

Who handles media inquiries for Candel Therapeutics?

Media inquiries are handled by Kyle Evans, Account Director at ICR Westwicke, reachable at CandelPR@westwicke.com.

What types of cancer are targeted by Candel Therapeutics' platforms?

Candel Therapeutics focuses on treating solid tumors through its immuno-oncology platforms.

Where is Candel Therapeutics based?

Candel Therapeutics is based in Massachusetts, USA.

Stock CADL logo
Candel Therapeutics, Inc.

Nasdaq:CADL

CADL Rankings

#3801 Ranked by Market Cap
N/A Ranked by Dividends

CADL Stock Data

194.72M
32.09M
33.27%
21.75%
4.97%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
NEEDHAM